SEHI New first-in-class treatment for Alzheimer’s disease

  • Edition: 2017
  • Research center: Fundació Bosch i Gimpera
  • Scientific Area: Pharmacology
  • Business area: Therapeutic
  • Status: In development
  • Contact:

Nearly 50 million people worldwide suffer from Alzheimer’s disease (AD), and it is expected that this figure will almost double every 20 years as a result of an ageing population. Current treatments tackle the symptoms, temporarily improving memory, but they are unable to stop the disease from progressing. There is an urgent need for treatments to combat AD to prevent, or at least delay, the onset of cognitive decline.


  • To work on a treatment for AD based in a new mechanism of action, which could help tackle brain inflammation, one of the early signs of the disease.

See project infographic:


Problem to Solve

AD is a multifactorial disorder involving several pathological mechanisms. There are currently several pharmacological research projects focussing on slowing or reversing the progress of AD. However, they mostly target the physiology of just two proteins, beta-amyloid and tau, and their ability to stop the disease from progressing has yet to be proved.

Since the global costs of AD and dementia are estimated to be around $600 billion, including the cost for patients as well as caregivers, it is critical to explore new targets with the potential to effectively treat these diseases, either as a standalone treatment or in combination with current drugs.


Small-molecules that target a key mechanism in the inflammation process, reducing neuro-inflammation and neuro-degeneration biomarkers and leading to a positive outcome in AD. The team has already found preliminary evidence of improvements to both cognitive decay and the neuropathological markers present in murine models for AD.

Level of Innovation

A first-generation of small-molecules with a new mechanism of action for AD and drug-like properties has already been developed. However, they do not show good Brain Blood Barrier permeability, which is critical to reach the focus of the disease, and serious efforts will be put to overcome this issue.


Project leader

Carles Galdeano

Fundació Bosch i Gimpera / Universitat de Barcelona

Postdoctoral researcher

Christian Griñán

Fundació Bosch i Gimpera / Universitat de Barcelona

PhD Student in Pharmacology

Dolors Puigoriol

Fundació Bosch i Gimpera / Universitat de Barcelona

Professor in Pharmacology

Mercè Pallàs

Fundació Bosch i Gimpera / Universitat de Barcelona

Associate Professor of Organic and Medicinal Chemistry at the Faculty of Pharmacy

Santiago Vázquez Cruz

UB - Universitat de Barcelona

PhD Student in Medicinal Chemistry

Sandra Codony

Fundació Bosch i Gimpera / Universitat de Barcelona

PhD student in Medicinal Chemistry

Rosana Leiva

Fundació Bosch i Gimpera / Universitat de Barcelona

Head of valorisation and licensing unit

Inma Iñiguez Izquierdo

Fundació Bosch i Gimpera / Universitat de Barcelona



Andrés G. Fernández

Ferrer Advanced Biotherapeutics


Obra social “la Caixa”
Caixa Capital Risc